**An FDA advisory committee's July 2026 vote provides the main recent catalyst for trader sentiment on BPC-157 reaching Category 1 status.** The Pharmacy Compounding Advisory Committee recommended 8-6-1 adding both the free base and acetate forms to the 503A Bulks List despite FDA staff objections citing insufficient human safety and efficacy data, primarily from preclinical studies. Removal from Category 2 in April 2026 lifted prior restrictions but did not authorize compounding or confer Category 1 placement. Any final move requires formal notice-and-comment rulemaking, a multi-month process that typically spans 8–24 months even after a favorable recommendation. Limited clinical evidence and the non-binding nature of the advisory vote continue to shape assessments of near-term resolution timelines.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоНОВЕ
Dec 31, 2026
December 31, 2026
45%
$4,143 Обс.
December 31, 2026
$2,141 Обс.
45%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**An FDA advisory committee's July 2026 vote provides the main recent catalyst for trader sentiment on BPC-157 reaching Category 1 status.** The Pharmacy Compounding Advisory Committee recommended 8-6-1 adding both the free base and acetate forms to the 503A Bulks List despite FDA staff objections citing insufficient human safety and efficacy data, primarily from preclinical studies. Removal from Category 2 in April 2026 lifted prior restrictions but did not authorize compounding or confer Category 1 placement. Any final move requires formal notice-and-comment rulemaking, a multi-month process that typically spans 8–24 months even after a favorable recommendation. Limited clinical evidence and the non-binding nature of the advisory vote continue to shape assessments of near-term resolution timelines.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Ринок відкрито: Jun 22, 2026, 10:10 PM ET
Обсяг
$4,143Дата завершення
Jan 1, 2027Ринок відкрито
Jun 22, 2026, 10:10 PM ETВирішувач
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**An FDA advisory committee's July 2026 vote provides the main recent catalyst for trader sentiment on BPC-157 reaching Category 1 status.** The Pharmacy Compounding Advisory Committee recommended 8-6-1 adding both the free base and acetate forms to the 503A Bulks List despite FDA staff objections citing insufficient human safety and efficacy data, primarily from preclinical studies. Removal from Category 2 in April 2026 lifted prior restrictions but did not authorize compounding or confer Category 1 placement. Any final move requires formal notice-and-comment rulemaking, a multi-month process that typically spans 8–24 months even after a favorable recommendation. Limited clinical evidence and the non-binding nature of the advisory vote continue to shape assessments of near-term resolution timelines.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Обсяг
$4,143Дата завершення
Jan 1, 2027Ринок відкрито
Jun 22, 2026, 10:10 PM ETВирішувач
0x65070BE91...**An FDA advisory committee's July 2026 vote provides the main recent catalyst for trader sentiment on BPC-157 reaching Category 1 status.** The Pharmacy Compounding Advisory Committee recommended 8-6-1 adding both the free base and acetate forms to the 503A Bulks List despite FDA staff objections citing insufficient human safety and efficacy data, primarily from preclinical studies. Removal from Category 2 in April 2026 lifted prior restrictions but did not authorize compounding or confer Category 1 placement. Any final move requires formal notice-and-comment rulemaking, a multi-month process that typically spans 8–24 months even after a favorable recommendation. Limited clinical evidence and the non-binding nature of the advisory vote continue to shape assessments of near-term resolution timelines.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання